| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Traws Pharma, Inc. (TRAW) has 11 insiders with recent SEC Form 4 filings, including 10 buys and 0 sells. TRAW is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 597.7K | $508.2K | - | |
| COO | 150.6K | $128.1K | - | |
| CEO | 147.8K | $125.6K | - | |
| Other | 116.0K | $98.6K | - | |
| Other | 113.9K | $96.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 27, 2018 | Hoffman Michael B | Director | Buy | 2,211,765 | $0.00 | - | +225.5% | |
| Apr 27, 2018 | Reddy E Premkumar | Director | Buy | 282,350 | $0.00 | - | +73.2% | |
| Apr 27, 2018 | 683 Capital Management, LLC | 10% Owner | Buy | 11,838,235 | $0.43 | $5,031,249.88 | +444.2% | |
| Feb 8, 2018 | Tyndall Capital Partners L P | 10% Owner | Buy | 1,100,000 | $1.01 | $1,111,000.00 | +110.3% | |
| Feb 8, 2018 | Marino James J | Director | Buy | 50,000 | $0.00 | - | +137.7% | |
| Feb 8, 2018 | 683 Capital Management, LLC | 10% Owner | Buy | 200,000 | $1.04 | $207,120.00 | +8.1% | |
| Apr 26, 2017 | Guerin Mark Patrick | Chief Financial Officer | Buy | 1,429 | $2.10 | $3,000.90 | +38.4% | |
| Apr 26, 2017 | Kumar Ramesh80 | President And CEO | Buy | 23,810 | $2.10 | $50,001.00 | +30.4% | |
| Apr 26, 2017 | Reddy E Premkumar | Director | Buy | 119,048 | $2.10 | $250,000.80 | +44.6% | |
| Apr 26, 2017 | Marino James J | Director | Buy | 11,906 | $2.10 | $25,002.60 | +48.8% |